AbbVie Inc. $ABBV Stake Raised by Provenance Wealth Advisors LLC

Posted by Stanley Muller on Nov 4th, 2026

Provenance Wealth Advisors LLC raised its holdings in AbbVie Inc. (NYSE:ABBV – Free Report) by 697.6% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 12,482 shares of the company’s stock after buying an additional 10,917 shares during the quarter. Provenance Wealth Advisors LLC’s holdings in AbbVie were worth $3,265,000 at the end of the most recent quarter.

Other hedge funds have also recently made changes to their positions in the company. Burk Holdings LLC bought a new position in shares of AbbVie during the second quarter valued at approximately $30,000. Marquette Asset Management LLC boosted its holdings in AbbVie by 52.2% in the second quarter. Marquette Asset Management LLC now owns 140 shares of the company’s stock valued at $35,000 after acquiring an additional 48 shares in the last quarter. Principia Wealth Advisory LLC boosted its holdings in AbbVie by 38.9% in the second quarter. Principia Wealth Advisory LLC now owns 157 shares of the company’s stock valued at $40,000 after acquiring an additional 44 shares in the last quarter. IMG Wealth Management Inc. increased its position in AbbVie by 3,060.0% during the 2nd quarter. IMG Wealth Management Inc. now owns 158 shares of the company’s stock valued at $40,000 after purchasing an additional 153 shares during the period. Finally, Tacita Capital Inc purchased a new position in AbbVie during the 2nd quarter valued at $42,000. 70.23% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at AbbVie

In related news, EVP Nicholas Donoghoe sold 32,710 shares of the firm’s stock in a transaction that occurred on Friday, August 14th. The stock was sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the completion of the transaction, the executive vice president owned 74,430 shares of the company’s stock, valued at $18,607,500. This trade represents a 30.53% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.06% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on the stock. The Goldman Sachs Group lifted their target price on shares of AbbVie from $258.00 to $294.00 and gave the company a “neutral” rating in a research note on Friday, October 23rd. Argus increased their price target on shares of AbbVie from $250.00 to $270.00 in a research note on Tuesday, August 4th. Wells Fargo & Company raised their price objective on shares of AbbVie from $300.00 to $340.00 and gave the stock an “overweight” rating in a report on Monday. Canaccord Genuity Group lifted their price objective on AbbVie from $290.00 to $338.00 and gave the company a “buy” rating in a research report on Monday. Finally, JPMorgan Chase & Co. upped their target price on AbbVie from $285.00 to $300.00 and gave the stock an “overweight” rating in a report on Thursday, October 8th. One research analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and six have given a Hold rating to the company’s stock. According to data from MarketBeat.com, AbbVie presently has a consensus rating of “Moderate Buy” and an average price target of $296.88.

View Our Latest Stock Analysis on AbbVie

Key Headlines Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

Positive Sentiment: AbbVie raised its 2026 outlook, projecting EPS of $13.95–$13.99 and revenue of $67.8 billion, both slightly above consensus at the midpoint. Its latest quarter also beat analyst estimates, with revenue up 10.3% year over year. Q3 earnings outlook and pipeline progress
Positive Sentiment: AbbVie expanded its Oxford R&D facility as part of an investment exceeding £120 million, signaling continued commitment to research and development. Reuters: Oxford R&D expansion
Positive Sentiment: The company expanded its migraine-drug partnership with Brise in a deal potentially worth up to $757 million, adding to its pipeline prospects. AbbVie-Brise license deal
Positive Sentiment: Several analysts raised their price targets after the quarterly results, reflecting confidence in AbbVie’s growth transition. Analyst target increases
Negative Sentiment: Fourth-quarter EPS guidance of $3.83–$3.87 is below the $3.89 consensus, despite revenue guidance of $18.4 billion topping expectations. That earnings shortfall could temper the otherwise stronger full-year outlook.
Negative Sentiment: After a strong run, valuation concerns remain: one recent analysis described the shares as stretched and questioned how much further growth from Skyrizi and pipeline deals is already reflected in the price. Valuation and upside analysis

AbbVie Price Performance

NYSE:ABBV opened at $285.88 on Wednesday. The firm has a market capitalization of $505.09 billion, a P/E ratio of 49.20, a PEG ratio of 1.31 and a beta of 0.20. AbbVie Inc. has a one year low of $190.75 and a one year high of $298.74. The company’s 50-day simple moving average is $270.23 and its 200 day simple moving average is $237.89.

AbbVie (NYSE:ABBV – Get Free Report) last announced its earnings results on Friday, October 30th. The company reported $3.82 earnings per share for the quarter, beating analysts’ consensus estimates of $3.73 by $0.09. AbbVie had a net margin of 15.67% and a negative return on equity of 435.41%. The business had revenue of $17.40 billion during the quarter, compared to the consensus estimate of $17.32 billion. During the same quarter last year, the firm earned $1.86 earnings per share. The business’s revenue for the quarter was up 10.3% on a year-over-year basis. On average, equities research analysts expect that AbbVie Inc. will post 14.00 earnings per share for the current fiscal year.

AbbVie Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, February 16th. Investors of record on Friday, January 15th will be paid a $1.82 dividend. This represents a $7.28 annualized dividend and a dividend yield of 2.5%. The ex-dividend date is Friday, January 15th. This is an increase from AbbVie’s previous quarterly dividend of $1.73. AbbVie’s dividend payout ratio (DPR) is currently 119.10%.

AbbVie Company Profile

(Free Report)

AbbVie Inc (NYSE: ABBV) is a global biopharmaceutical company that discovers, develops and commercializes medicines and other healthcare products. Its portfolio focuses on immunology, oncology, neuroscience, aesthetics and eye care, serving patients and healthcare providers in markets around the world.

The company’s key products include immunology medicines such as Skyrizi and Rinvoq; neuroscience treatments including Vraylar, Ubrelvy and Qulipta; and oncology products such as Imbruvica and Venclexta.